` AGL (Angle PLC) vs FTSE All Share Index Comparison - Alpha Spread

AGL
vs
F
FTSE All Share Index

Over the past 12 months, AGL has outperformed FTSE All Share Index, delivering a return of -75% compared to the FTSE All Share Index's 0% growth.

Stocks Performance
AGL vs FTSE All Share Index

Loading
AGL
FTSE All Share Index
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
AGL vs FTSE All Share Index

Loading
AGL
FTSE All Share Index
Difference
www.alphaspread.com

Performance By Year
AGL vs FTSE All Share Index

Loading
AGL
FTSE All Share Index
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Angle PLC vs Peers

FTSE All Share Index
AGL
ABT
ISRG
BSX
SYK
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Angle PLC
Glance View

Market Cap
3.4m GBX
Industry
Health Care

ANGLE Plc operates as a holding company, through its subsidiaries engages in providing products in cancer diagnostics and foetal health. The company is headquartered in Guildford, Surrey and currently employs 102 full-time employees. The company went IPO on 2004-03-17. The Company’s lead product is the Parsortix cell separation system, which captures very rare cells from the blood. This includes circulating tumor cells (CTCs) in cancer patient blood even when there is less than one CTC in one billion healthy cells. The Parsortix cell separation system uses a microfluidic technology in the form of a one-time use cassette to capture and then harvest circulating tumor cells (CTCs) from blood. The cassette captures CTCs based on their less deformable nature and larger size compared to other blood components. The Company’s translational research includes ovarian cancer, breast cancer, prostate cancer and small cell lung cancer.

AGL Intrinsic Value
11.28 GBX
Undervaluation 79%
Intrinsic Value
Price
Back to Top